Skip to content
Open access

Brain‐derived plasma p‐tau217 shows enhanced dynamic range for Alzheimer's disease neuropathological change

Sep 2026 · Alzheimer's & Dementia · Vol 22 · 0 citations · 38 references
Medicine

TL;DR

Brain‐derived p‐tau217 may reduce these off‐target effects of Alzheimer's disease pathology, but its performance against neuropathology has not been evaluated.

Abstract

Plasma phosphorylated tau (p‐tau), particularly p‐tau217, is a highly specific biomarker of Alzheimer's disease (AD) pathology. However, plasma p‐tau217 can be elevated in rare non‐AD conditions. Brain‐derived (BD) p‐tau217 may reduce these off‐target effects, but its performance against neuropathology has not been evaluated.

Read PDF

Similar papers

Open access Sep 2026

Cerebrospinal Fluid p75 Neurotrophin Receptor Ectodomain Levels Across Clinically Diagnosed Alzheimer's Disease, Late‐Life Depression, and Healthy Aging: A Preliminary Cross‐Sectional Study

The p75 neurotrophin receptor ectodomain (p75NTR‐ECD) has been implicated in amyloid‐β‐related neurotoxicity, but cerebrospinal fluid (CSF) levels in late‐life depression (LLD) remain uncertain. We compared clinically diagnosed Alzheimer's disease (AD), LLD, and healthy controls (HC) and reassessed exploratory symptom...

W. Omori, N. Kajitani, M. Okada-Tsuchioka et al. · 0 citations
Open access Sep 2026

Astrocyte reactivity identifies p-tau217-positive individuals at elevated risk of cognitive decline across the Alzheimer’s disease continuum

It is shown that elevated plasma GFAP significantly modulates the association between p-tau217 and both cross-sectional cognitive severity and longitudinal clinical decline, and support that astrocyte reactivity is associated with greater cognitive impairment and faster clinical decline among individuals with elevated...

B. Bellaver, G. Povala, P. C. L. Ferreira et al. · 0 citations
Review Open access Sep 2026

Rethinking tau‐targeted therapy in Alzheimer's disease: Toward a dual biomarker strategy

A dual‐domain framework is proposed in which tau‐targeted therapies are evaluated using complementary measures of aggregated tau burden and biologically defined soluble tau states, and treatment‐induced increases should be considered favorable only when they accompany aggregate reduction and evidence of a less pathogen...

C. Teunissen, L. Pini, B. Imbimbo · 0 citations
Review Open access Sep 2026

CSF Tau and Amyloid Biomarkers in Cognitive Impairment Across the ALS–FTD Spectrum: A Systematic Narrative Review and Evidence Map

Cognitive impairment is an important non‐motor manifestation of amyotrophic lateral sclerosis (ALS), particularly across the ALS–frontotemporal dementia (ALS–FTD) spectrum. Cerebrospinal fluid (CSF) tau and amyloid biomarkers may reflect nonspecific neurodegenerative injury, concomitant Alzheimer disease (AD) pathology...

Aasim Ali, Muhammad Arif, Usama Ashraf et al. · 0 citations
Open access Sep 2026

TMEM106B is a selective modulator of TDP‐43 pathology in Alzheimer's disease

Co‐pathologies – including Lewy body, vascular, and TDP‐43 lesions – are common in Alzheimer's disease (AD), contributing to its clinical and pathological heterogeneity. Genetic risk factors may drive mixed pathology presentation, but their influence on the development of specific co‐pathologies remains unclear.

Madison M. Reeves, Anna Calliari, Tiffany W. Todd et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.